Clinical Trial Update: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] [Phase 3]

View source ↗

Summary

Phase 3 DESTINY-Breast04 trial evaluating trastuzumab deruxtecan versus investigator's choice in HER2-low breast cancer; results were posted in June 2023 while …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-06-15